

On page 10, line 32 after recitation of "1b (pCV-J4L6S)." insert -- 5' UTR

for HC-J4 is SEQ ID NO:47, 5' UTR for pCV - J4L6S is SEQ ID NO:48, 5' UTR for pCV-H77C is SEQ ID NO: 49, 3' UTR - 3' variable region for HC-J4 is SEQ ID NO 50 and 53, 3' UTR - 3' variable region for pCV-J4L6S is SEQ ID NO:51 and 54, 3' UTR - 3' variable region for pCV-H77C is SEQ ID NO:52 and 54; 3' UTR - 3' conserved region for H77, pCV-J4L6S and pCV - H77C is SEQ ID NO 55.

On page 12, last line after recitation of Accession No. insert -- 209596 --.

On page 11, line 20 after recitation of "strain HC-J4" insert -- (SEQ ID NO:4) --.

On page 11, line 21 after recitation of "amino acid sequence" insert -- (SEQ ID NO:3) --.

On page 11, line 29 after recitation of "clone pH 77CV-J4" insert -- (SEQ ID NO:6) --.

On page 11, line 31 after recitation of "chimeric 1a/1b clone" insert -- (SEQ ID NO:5) --.

On page 11, line 34 after recitation of "1a infectious clone pCV-H77C" insert -- pCV-H77C has SEQ ID NOS:56, 57 and 58; pCV-H77C (-98X) has SEQ ID NO:59; pCV-H77C (-42X) has SEQ ID NO:60; pCV-H77C (X-52) has SEQ ID NO:61; pCV-H77C(X) has SEQ ID NO:62; pCV-H77 C(+49X) has SEQ ID NO:63; pCV-H77C (VR-24) has SEQ ID NO:64; and pCV-H77C (-U/UC) has SEQ ID NO:65).

On page 29, Table 1, line 4, after recitation of "H9261F" insert -- SEQ ID NO:7 --; at line 5 after recitation of "H3' x 58R" insert -- SEQ ID NO:8 --; at line 6 after recitation of "H9282F" insert -- SEQ ID NO:9 --; at line 7 after recitation "H3' X 45R" insert -- SEQ ID NO:10 --; at line 8 after recitation of "H9375F" insert -- SEQ ID NO:11 --;

at line 9 after recitation of "H3' X -35R" insert -- SEQ ID NO:12; at line 10 after recitation of "H9386F" insert -- SEQ ID NO:13 --; at line 11 after recitation of "H3' X - 38R" insert -- SEQ ID NO:14 --; at line 12 after recitation of "H1" insert -- SEQ ID NO:15 --; at line 13 after recitation of "H9417R" insert -- SEQ ID NO:17 --.

On page 41, line 1 after recitation of "(5'-GCCTATTGGCCTGGAGTGGTT AGCTC - 3') insert -- SEQ ID NO:18 --; at line 6 after recitation of: AGGATGGCCTTAAGG CCTGGAGTGGTTAGCTCCCCGTTCA - 3')" insert -- SEQ ID NO:19 --.

On page 51, line 1, after recitation of "H2751S (Cla I/Nde I)" insert --SEQ ID NO:20 --; at line 3 after recitation of " H2870R" insert -- SEQ ID NO:21 --; at line 5 after recitation of "H7851S" insert -- SEQ ID NO:22 --; at line 7 after recitation of "H9173 R(P-M)" insert -- SEQ ID NO:23 --; at line 9 after the recitation of "H9140S (P-M)" insert - - SEQ ID NO:24 --; at line 11 after the recitation of "H9417R" insert -- SEQ ID NO:25 --; at line 14 after recitation of "J4-2271S" insert -- SEQ ID NO:26 --; at line 16 after recitation of "J4-2776R (Nde I)" insert -- SEQ ID NO:27 --.

After page 62 of the "Abstract of the Disclosure" insert -- Sequence Listing -- page number 1 through 61.

IN THE CLAIMS

Please cancel claims 1-41 without prejudice.

Please amend the following claims:

42. (Amended) A composition comprising a purified and isolated nucleic acid molecule [of claim 1] suspended in a suitable amount of a pharmaceutically acceptable diluent or excipient, said nucleic acid molecule encodes human hepatitis C